How many patients are eligible for anti-TNF therapy in the UK?

Open Access
Publisher Website
Google Scholar
Abstract
Sir, Anti‐tumour necrosis factor (TNF) therapies (infliximab and etanercept) are the first scientifically designed biological response modifiers to be licensed for use in rheumatoid arthritis (RA). Other novel therapies, such as interleukin 1 receptor antagonists, are in development. A British Society of Rheumatology (BSR) working party has prepared guidelines for the use of these drugs, restricting their use initially to those who have failed a satisfactory trial of conventional anti‐rheumatoid arthritis drugs, have active disease (defined as DAS28 score &!hairsp;>5.1) and are not excluded due to any contraindications such as infection or malignancy.

This publication has 0 references indexed in Scilit: